SITC Cancer Immunotherapy CONNECT

SITC 2022 Logo.png

Submit your Cutting-edge Research

SITC 2022 is now accepting submissions for Regular abstracts, Young Investigator Award abstracts and/or applications for Late-breaking abstracts. The abstract deadline is 5 p.m. PDT on July 28, 2022.

LEARN MORE

SITC 2022 Logo.png

Register Now

Join us at our 37th Annual Meeting & Pre-Conference Programs on Nov. 8–12, 2022 at the Boston Convention & Exhibition Center in Boston, MA. Virtual participation also available.

REGISTER NOW

The CheckPoints

The CheckPoints: Rockin' for a Cure

Rock out with The CheckPoints! The band is set to perform at Buddy Guy’s Legends in Chicago on June 5, 2022.

VIP tickets now available!

LEARN MORE

Rosenberg Scholars Award

Nominate an Emerging Leader in IO

SITC is seeking the best and brightest for the 2022 Steven A. Rosenberg Scholars Award, one of the society's most prestigious opportunities for early career scientists.

LEARN MORE

Call for Proposals

Call for Proposals

For the first time, SITC is holding an open call for proposals! SITC leadership wants to hear ideas from its members, which will inspire content for future webinars, workshops, Annual Meeting sessions and more.

SUBMIT A PROPOSAL

SITCMedscape

Comprehensive Learning Center:
Year 8

Immunotherapy - A Revolutionary Approach for Difficult-to-Treat Cancers. CME activities developed through a partnership between Medscape and SITC.

Learn More

SITC CIG App Homescreen Cropped

Download the new SITC Clinical Practice Guidelines (CPG) Mobile App!
The first and only immunotherapy-specific clinical practice guidelines app featuring guideline content and expert panel recommendations in an easy-to-navigate format. The app includes interactive tools, bookmarks, and advanced search capabilities.
Available for FREE for iOS and Android.

Learn More

New SITC Clinical Practice Guidelines Published

  • Acute Leukemia
  • Breast Cancer
  • Hepatocellular Carcinoma
  • Immune Checkpoint Inhibitor-related Adverse Events
  • Urothelial Cancer
Free companion educational webinars available.


jitc.png

JITC Increases Impact Factor to 13.751
The Journal for ImmunoTherapy of Cancer's (JITC) Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 5% percent of all journals published in the category of immunology and top 7% in the category of oncology.

Patient

Explore resources and educational opportunities for cancer patients and those who advocate for them.

Explore

 

 

 

 

Clinician

Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.

Explore

 

 

 

 

Researcher

Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.

Explore

 

 

 

 

Latest Discussions

  • Advancements in the field of neurosurgery are occurring at an increasingly rapid rate. The integration of these advances into clinical practice often lags behind the rate at which they emerge in the literature. Therefore, a critical appraisal of the most ...

  • Posted in: Women in SITC

    I will share this in my med onc group friends in facebook Sent from my iPhone, please excuse any typos and brevity.

  • Posted in: Women in SITC

    Hello Women of SITC! I want to share information about an empowering program just for women in our field: the Society for Immunotherapy of Cancer's (SITC's) Women in Cancer Immunotherapy Network (WIN) Leadership Institute . Applicants will be selected ...

Follow the SITC Twitter Feed.

 

Connect with colleagues at these Upcoming Events.

 

Ignite the SITC Sparkathon

Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.

 

Learn More

 

The Journal & The Blog

Journal for ImmunoTherapy of Cancer

An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.

Learn More

 

Making Cure a Reality

It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

 

Learn More